Previous close | 18.64 |
Open | 18.57 |
Bid | 18.46 x 200 |
Ask | 18.52 x 200 |
Day's range | 18.22 - 18.91 |
52-week range | 13.82 - 24.21 |
Volume | |
Avg. volume | 620,435 |
Market cap | 1.664B |
Beta (5Y monthly) | 1.98 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.
Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.